



ESME Ovarian Cancer

Publications

Health Data & partnership Department

Publications in peer-review journals

1. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Uncancer database.
De Nonville A, Zemmour C, Franck S, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, De la Motte Rouge T, Colombo PE, Sauterey B, Leblanc E, Pomel C, Marchal F, Barranger E, Savoye MA, Guillemet C, Petit T, Pautier P, Rouzier R, Gladieff L, Simon G, Courtinard C, Dabatier R.
Gyn Oncol. 2021 Oct;163(1):64-71 <https://doi.org/10.1016/j.ygyno.2021.07.019>
2. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
Thomas QD, Boussere A, Classe JM, Pomel C, Costa H, Rodrigues M, Ray-Coquard I, Gladieff L, Rouzier R, De la Motte Rouge T, Gouy S, Barranger E, Sabatier R, Floquet A, Marchal F, Guillemet C, Polivka V, Martin AL, Colombo PE, Fiteni F.
Gynecol Oncol. 2022 Aug;S0090-8258 <https://doi.org/10.1016/j.ygyno.2022.08.005>
3. Real-world data on newly diagnosed BRCA-mutated high-grade epithelial ovarian cancers: the French national multicenter ESME database.
Bini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, Marchal F, Provansal M, Campion L, Causeret S,ourgou S, Ray-Coquard I, Classe JM, Pomel C, De la Motte Rouge T, Barranger E, Savoye AM, Guillemet C, Gladieff L, Demarchi M, Rouzier R, Vourtinard C, Romeo C, Joly F.
Cancers. 2022 Aug;14(16):4040 <https://doi.org/10.3390/cancers14164040>

Publications in peer-review journals

4. Efficacy of chemotherapy according to BRCA status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse.
Brouillard-Saby F, Saint-Martin C, Ray-Coquard I, Gladieff L, Pomel C, Colombo PE, Classe JM, Chevire M, Joly F, De la Motte Rouge T, Floquet A, Sabatier R, Barranger E, Costaz H, Leblanc E, Marchal F, Pautier P, Bosquet L, Rodrigues M.
Int J Gynecol Cancer. 2023 Jan <https://doi.org/10.1136/ijgc-2022-003993>

Scientific communications in congress

1. [Poster] Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment.
Romeo C, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, et al. 2019
European Society of Gynaecological Oncology (ESGO) 2019
2. [Poster] Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France.
Rodrigues M, Joly F, Ray-Coquard I, Costaz H, Classe JM, Floquet A, et al. Ann Oncol. 2021 Dec;32(Suppl 5):S741–2 (746P)
European Society of Medical Oncology (ESMO) 2021
<https://doi.org/10.1016/j.annonc.2021.08.1188>
3. [Poster] Analyses des données de vie réelle des patientes traitées en première ligne pour un cancer épithélial de l'ovaire de stade avancé de haut grade, éligibles à un traitement de maintenance par niraparib en France.
Joly F, Rodrigues M, Ray-Coquard I, Costaz H, Classe JM, Floquet A, et al. 2021.
Société française d'onco-gynécologie (SFOG) 2021
4. [Abstract only] ODALIE Study, a retrospective analysis of a real-life cohort of patients with de novo advanced high grade epithelial ovarian cancer treated with a first-line platinum- and taxane-based chemotherapy combined with bevacizumab.
Lagarde-Betrian S, Penault-Llorca F, Pautier P, Joly F, Ray-Coquard I, Costaz H, et al. J Clin Oncology. 2022 jun;40(Suppl 16):e17577
European Society of Medical Oncology (ESMO) 2022
https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.e17577

Scientific communications in congress

5. [Poster] CA125 longitudinal decline kinetic is complementary to BRCA testing in first-line high grade serous ovarian carcinoma (HGSOC) patients (pts).
Becker O, Chevrier M, Gladieff L, Joly F, Ray-Coquard I, Floquet A, et al. Ann Oncol. 2022
<https://doi.org/10.1016/j.annonc.2022.07.724>
European Society of Medical Oncology (ESMO) 2022
6. [Poster] Benefit of bevacizumab according to CA125 decline kinetic in first-line high grade serous ovarian carcinoma (HGSOC) patients in real-life setting.
Becker O, Chevrier M, Gladieff L, Joly F, Ray-Coquard I, Floquet A, et al. Int J Gyn Can 2022
<http://dx.doi.org/10.1136/ijgc-2022-ESGO.576>
European Society of Gynaecological Oncology (ESGO) 2022
7. [Poster] Primary and interval debulking surgery in advanced ovarian cancer: Real-World Clinical Outcomes of Patients in 1st line setting, Analysis from the French national ESME-Unicancer database.
Costaz H, Bousserre A, Thomas QD, Ray-Coquard I, Pomel C, Gladieff L, et al. Int J Gyn Can 2022
<http://dx.doi.org/10.1136/ijgc-2022-ESGO.548>
European Society of Gynaecological Oncology (ESGO) 2022
8. [Poster] Impact of age on first line treatments of ovarian cancer and their outcomes: results of the Unicancer ESME OVR real-life database.
Bengrine L, Fouquier A, Ray-Coquard I, Joly F, Rodrigues M, Sauterey B, et al. Int J Gyn Can 2022
<http://dx.doi.org/10.1136/ijgc-2022-ESGO.741>
European Society of Gynaecological Oncology (ESGO) 2022

Scientific communications in congress

9. [Poster] Initial management and long-term outcome of low-grade serous ovarian exploring role of surgery and maintenance therapy in the French multicentre ESME database
Papazyan T, Martin E, Pautier P, Guérin-Charbonnel C, Rowinski E, Lecuru F, et al.
<https://doi.org/10.1016/j.annonc.2023.09.1974>
European Society of Medical Oncology (ESMO) 2023

10. [Poster] Patient Characteristics, Treatment Patterns And Real-World Effectiveness Of Niraparib In France: An ESME Retrospective Study In Recurrent Ovarian Cancer Patients Treated With Niraparib Maintenance
Gladieff L, Macouillard P, Toussaint P, El-Mouaddin N, Jacquemin V, Fages A, et al.
European Society of Gynaecological Oncology (ESGO) 2024